Drug Profile
Facinicline
Alternative Names: MEM-63908; R-4996Latest Information Update: 30 Mar 2010
Price :
$50
*
At a glance
- Originator Memory Pharmaceuticals
- Developer Roche
- Class Antidementias; Nootropics
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 30 Mar 2010 No development reported - Phase-I for Alzheimer's disease in Canada (PO)
- 19 Dec 2008 Adverse events and pharmacokinetic data from phase I trials Alzheimer's disease released by Memory Pharmaceuticlas
- 26 Sep 2008 Memory Pharmaceuticals completes its phase I trial programme in Alzheimer's disease in Canada